Celladon Corp Stock Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 25.22M | Sales 2025 * | 32.65M | Capitalization | 3.95M |
---|---|---|---|---|---|
Net income 2024 * | -24M | Net income 2025 * | -9M | EV / Sales 2024 * | 0.16 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.74
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.21% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
Director of Finance/CFO | 58 | 23-04-12 | |
James Vollins
CMP | Compliance Officer | 55 | 23-04-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-07-17 | |
Thomas Dietz
CHM | Chairman | 60 | 16-03-21 |
David Apelian
CEO | Chief Executive Officer | 59 | 17-06-13 |
1st Jan change | Capi. | |
---|---|---|
+2.62% | 42.75B | |
+47.70% | 41.61B | |
+12.08% | 41.34B | |
-8.83% | 26.59B | |
+7.98% | 25.49B | |
-22.45% | 18.12B | |
+31.23% | 12.24B | |
-1.37% | 11.76B | |
+8.48% | 11B |